{
    "nct_id": "NCT05947851",
    "official_title": "A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)",
    "inclusion_criteria": "* Confirmed diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and active disease clearly documented to initiate therapy.\n* Deletion (Del) (17p) status, tumor protein 53 (TP53) mutation status, immunoglobulin heavy chain gene (IGHV) mutation status and Bruton's tyrosine kinase (BTK)-C481 mutation status results required before randomization for Part 2 participants only.\n* Relapsed or refractory to at least 1 prior available therapy.\n* Have at least 1 marker of disease burden.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization.\n* Has a life expectancy of at least 3 months.\n* Has the ability to swallow and retain oral medication.\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization.\n* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening.\n* Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria.\n* Participants with adequate organ function with specimens collected within 7 days before the start of study intervention.\n* If capable of producing sperm, participant agrees to eliminate Nemtabrutinib: 12 days, Venetoclax: 1 month (30 days), Rituximab (rituximab biosimilar): not applicable; abstains from penile-vaginal intercourse as their preferred and usual lifestyle; OR uses prescribed contraception.\n* Participant assigned female sex at birth are eligible to participate if not pregnant or breastfeeding and are not a person of childbearing potential (POCBP) OR is a POCBP and uses a contraceptive method that is highly effective, has a negative highly sensitive pregnancy test, and abstains from breastfeeding.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection.\n* Has gastrointestinal (GI) dysfunction that may affect drug absorption.\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL.\n* Has an active infection requiring systemic therapy, such as intravenous (IV) antibiotics, during screening.\n* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease and/or acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening.\n* Has QT interval corrected (QTc) prolongation or other significant electrocardiogram (ECG) abnormalities.\n* Has a known allergy/sensitivity to nemtabrutinib or contraindication to venetoclax/rituximab (or rituximab biosimilar), or any of the excipients.\n* Has history of severe bleeding disorders (eg, hemophilia).\n* Has received prior systemic anticancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before randomization.\n* Has received prior B-cell lymphoma 2 inhibitor(s) (BCL2i) including venetoclax or Non-covalent Bruton's tyrosine kinase inhibitor (BTKi).\n* Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong or moderate inducers or CYP3A strong inhibitors.\n* Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention.\n* Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration.\n* Has a known psychiatric or substance use disorder that would interfere with the participant's ability to cooperate with the requirements of the study.\n* Participants who have not adequately recovered from major surgery or have ongoing surgical complications.",
    "miscellaneous_criteria": ""
}